Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 84Recruiting 35Terminated 22Active not recruiting 12Unknown 11Withdrawn 4Not yet recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Specimen Handling 15Biopsy 9Cyclophosphamide 8Magnetic Resonance Spectroscopy 7venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Carboplatin 3zanubrutinib 2prednylidene 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Vincristine 2Rituximab 2Radiotherapy, Intensity-Modulated 2Protein Subunit Vaccines 2Prednisone 2Nivolumab 2Melphalan 2Injections 2Gemcitabine 2E 7107 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Cetuximab × Clear all
NCT06102902 2026-05-13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡